Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Gradishar

Showing results (81-90 of 195) with videos related to

Pageof 20
Sort By:
Journal for Immunotherapy of Cancer|January 7, 2022
Role of Fcγ receptors in HER2-targeted breast cancer therapyAntonino Musolino, William J Gradishar, Hope S Rugo, et al.
Breast Cancer Research and Treatment|June 1, 2018
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapySarika Jain, Ami N Shah, Cesar A Santa-Maria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II studyWilliam J Gradishar, Luis A Meza, Bipinkumar Amin, et al.
Breast (Edinburgh, Scotland)|May 9, 2025
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologistsHope S Rugo, Aditya Bardia, William J Gradishar, et al.
Breast Cancer Research and Treatment|April 13, 2019
Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancerMartin Mutonga, Sedona Speedy, Alfred Rademaker, et al.
Annals of Surgery|September 10, 2021
De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough?Roi Weiser, Efstathia Polychronopoulou, Yong-Fang Kuo, et al.
Ebiomedicine|May 19, 2019
A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapyZhuan Zhou, Zhiwei Feng, Dong Hu, et al.
Cancer Investigation|October 24, 2007
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experienceRyan H Engel, Jennifer A Brown, Jamie H Von Roenn, et al.
Oncotarget|December 8, 2016
Developmental therapeutics for inflammatory breast cancer: Biology and translational directionsRicardo Costa, Cesar A Santa-Maria, Giovanna Rossi, et al.
Breast Cancer Research and Treatment|December 17, 2009
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group TrialStacy Moulder, Hailun Li, Molin Wang, et al.
Pageof 20

Showing results (81-90 of 195) with videos related to

Sort By:
Pageof 20
Journal for Immunotherapy of Cancer|January 7, 2022
Role of Fcγ receptors in HER2-targeted breast cancer therapyAntonino Musolino, William J Gradishar, Hope S Rugo, et al.
Breast Cancer Research and Treatment|June 1, 2018
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapySarika Jain, Ami N Shah, Cesar A Santa-Maria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II studyWilliam J Gradishar, Luis A Meza, Bipinkumar Amin, et al.
Breast (Edinburgh, Scotland)|May 9, 2025
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologistsHope S Rugo, Aditya Bardia, William J Gradishar, et al.
Breast Cancer Research and Treatment|April 13, 2019
Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancerMartin Mutonga, Sedona Speedy, Alfred Rademaker, et al.
Annals of Surgery|September 10, 2021
De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough?Roi Weiser, Efstathia Polychronopoulou, Yong-Fang Kuo, et al.
Ebiomedicine|May 19, 2019
A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapyZhuan Zhou, Zhiwei Feng, Dong Hu, et al.
Cancer Investigation|October 24, 2007
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experienceRyan H Engel, Jennifer A Brown, Jamie H Von Roenn, et al.
Oncotarget|December 8, 2016
Developmental therapeutics for inflammatory breast cancer: Biology and translational directionsRicardo Costa, Cesar A Santa-Maria, Giovanna Rossi, et al.
Breast Cancer Research and Treatment|December 17, 2009
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group TrialStacy Moulder, Hailun Li, Molin Wang, et al.
Pageof 20